Home LiteratureArticle Details
PMID: 20389023 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

The Journal of clinical investigation ·Vol. 120 ·No. 5 ·2010-05-00 ·Pages 1663-73

Corti D, Suguitan AL, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, Weiss RA, Sallusto F, Subbarao K, Lanzavecchia A

Abstract

The target of neutralizing antibodies that protect against influenza virus infection is the viral protein HA. Genetic and antigenic variation in HA has been used to classify influenza viruses into subtypes (H1-H16). The neutralizing antibody response to influenza virus is thought to be specific for a few antigenically related isolates within a given subtype. However, while heterosubtypic antibodies capable of neutralizing multiple influenza virus subtypes have been recently isolated from phage display libraries, it is not known whether such antibodies are produced in the course of an immune response to influenza virus infection or vaccine. Here we report that, following vaccination with seasonal influenza vaccine containing H1 and H3 influenza virus subtypes, some individuals produce antibodies that cross-react with H5 HA. By immortalizing IgG-expressing B cells from 4 individuals, we isolated 20 heterosubtypic mAbs that bound and neutralized viruses belonging to several HA subtypes (H1, H2, H5, H6, and H9), including the pandemic A/California/07/09 H1N1 isolate. The mAbs used different VH genes and carried a high frequency of somatic mutations. With the exception of a mAb that bound to the HA globular head, all heterosubtypic mAbs bound to acid-sensitive epitopes in the HA stem region. Four mAbs were evaluated in vivo and protected mice from challenge with influenza viruses representative of different subtypes. These findings reveal that seasonal influenza vaccination can induce polyclonal heterosubtypic neutralizing antibodies that cross-react with the swine-origin pandemic H1N1 influenza virus and with the highly pathogenic H5N1 virus.

MeSH Terms
Animals Antibodies, Monoclonal/chemistry Antibodies, Neutralizing/chemistry Binding Sites Dogs Epitope Mapping/methods Female Humans Immunoglobulin G/metabolism Influenza Vaccines/immunology Influenza, Human/prevention & control Leukocytes, Mononuclear/cytology Mice Mice, Inbred BALB C Mutation Orthomyxoviridae/metabolism Protein Binding
Chemicals
Antibodies, Monoclonal Antibodies, Neutralizing Immunoglobulin G Influenza Vaccines
Authors & Affiliations
14 authors, click to expand affiliations / ORCID
Corti Davide
Institute for Research in Biomedicine, Bellinzona, Switzerland.
Suguitan Amorsolo L
Pinna Debora
Silacci Chiara
Fernandez-Rodriguez Blanca M
Vanzetta Fabrizia
Santos Celia
Luke Catherine J
Torres-Velez Fernando J
Temperton Nigel J
Weiss Robin A
Sallusto Federica
Subbarao Kanta
Lanzavecchia Antonio
References (36)
36 references, click to expand
  1. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.
    PLoS One. 2008;3(12):e3942 PMID: 19079604
  2. Antibody recognition of a highly conserved influenza virus epitope.
    Science. 2009 Apr 10;324(5924):246-51 PMID: 19251591
  3. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation.
    Nature. 1981 Jan 29;289(5796):373-8 PMID: 6162101
  4. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza.
    Emerg Infect Dis. 2008 Jan;14(1):121-8 PMID: 18258091
  5. H1 and H7 influenza haemagglutinin structures extend a structural classification of haemagglutinin subtypes.
    Virology. 2004 Aug 1;325(2):287-96 PMID: 15246268
  6. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.
    Nat Med. 2004 Aug;10(8):871-5 PMID: 15247913
  7. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets.
    PLoS Med. 2009 Apr 21;6(4):e1000049 PMID: 19381279
  8. Evolution and ecology of influenza A viruses.
    Microbiol Rev. 1992 Mar;56(1):152-79 PMID: 1579108
  9. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin.
    Annu Rev Biochem. 2000;69:531-69 PMID: 10966468
  10. Disquisitions of Original Antigenic Sin. I. Evidence in man.
    J Exp Med. 1966 Sep 1;124(3):331-45 PMID: 5922742
  11. The predicted antigenicity of the haemagglutinin of the 1918 Spanish influenza pandemic suggests an avian origin.
    Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1871-6 PMID: 11779386
  12. Attacking the flu: neutralizing antibodies may lead to 'universal' vaccine.
    Nat Med. 2009 Nov;15(11):1251-2 PMID: 19893556
  13. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies.
    Influenza Other Respir Viruses. 2007 May;1(3):105-12 PMID: 19453415
  14. Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components.
    Virology. 2006 Sep 1;352(2):418-26 PMID: 16777168
  15. Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number.
    J Clin Invest. 1996 May 1;97(9):2074-80 PMID: 8621797
  16. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution.
    Nature. 1981 Jan 29;289(5796):366-73 PMID: 7464906
  17. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls.
    J Virol. 2005 Mar;79(5):2814-22 PMID: 15709000
  18. Antigenic determinants of influenza virus hemagglutinin. III. Competitive binding of antibodies directed against "common" and "strain-specific" antigenic determinants of A/Memphis/72 hemagglutinin.
    J Immunol. 1979 Aug;123(2):825-32 PMID: 88484
  19. Variation and infectivity neutralization in influenza.
    Immunology. 2006 Sep;119(1):1-7 PMID: 16925526
  20. Mapping the antigenic and genetic evolution of influenza virus.
    Science. 2004 Jul 16;305(5682):371-6 PMID: 15218094
  21. An epitope shared by the hemagglutinins of H1, H2, H5, and H6 subtypes of influenza A virus.
    Acta Virol. 1999 Aug;43(4):237-44 PMID: 10749369
  22. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype.
    J Virol. 2002 Feb;76(3):1369-78 PMID: 11773411
  23. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses.
    Nat Struct Mol Biol. 2009 Mar;16(3):265-73 PMID: 19234466
  24. Pandemic vaccine preparedness--have we left something behind?
    PLoS Pathog. 2009 Jun;5(6):e1000482 PMID: 19557166
  25. Comparative analyses of the specificities of anti-influenza hemagglutinin antibodies in human sera.
    J Virol. 1986 Jan;57(1):124-8 PMID: 3941436
  26. Fc receptor but not complement binding is important in antibody protection against HIV.
    Nature. 2007 Sep 6;449(7158):101-4 PMID: 17805298
  27. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies.
    Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):5986-91 PMID: 18413603
  28. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.
    PLoS Med. 2006 Sep;3(9):e360 PMID: 16968127
  29. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains.
    J Virol. 1993 May;67(5):2552-8 PMID: 7682624
  30. Structural basis of immune recognition of influenza virus hemagglutinin.
    Annu Rev Immunol. 1990;8:737-71 PMID: 2188678
  31. Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains.
    J Virol. 1994 Jan;68(1):517-20 PMID: 8254764
  32. Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses.
    Vaccine. 2009 Oct 9;27(43):5998-6003 PMID: 19665606
  33. Clonal dissection of the human memory B-cell repertoire following infection and vaccination.
    Eur J Immunol. 2009 May;39(5):1260-70 PMID: 19404981
  34. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.
    J Clin Microbiol. 1999 Apr;37(4):937-43 PMID: 10074505
  35. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype).
    Cell. 1982 Dec;31(2 Pt 1):417-27 PMID: 6186384
  36. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses.
    PLoS Pathog. 2009 Mar;5(3):e1000350 PMID: 19300497
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
1558-8238
Published
2010-05-00
Epub
2010-00-12
Pages
1663-73
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC2860935
Subset
IM
Grants
Medical Research Council · G0600369 · United Kingdom
Medical Research Council · G0801176 · United Kingdom
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com